Jump to content

PDRX - PD-Rx Pharmaceuticals


orion

Recommended Posts

Pd-Rx Pharmaceuticals Inc (OTCBB:PDRX) on 11/20/2018 declared a dividend of $ 2.2000 per share payable on December 12, 2018 to shareholders of record as of November 30, 2018. Dividend amount recorded is an increase of $ 1.54 from last dividend Paid.

 

https://www.dividendinvestor.com/dividend-news/20181120/dividend-announcement-pd-rx-pharmaceuticals-inc-otcbb-pdrx-on-11-20-2018-declared-a-dividend-of-$2.2000-per-share/

 

 

Shouldn't it be selling off given it's ex dividend date on a huge payout?

Link to comment
Share on other sites

  • Replies 109
  • Created
  • Last Reply

Top Posters In This Topic

Pd-Rx Pharmaceuticals Inc (OTCBB:PDRX) on 11/20/2018 declared a dividend of $ 2.2000 per share payable on December 12, 2018 to shareholders of record as of November 30, 2018. Dividend amount recorded is an increase of $ 1.54 from last dividend Paid.

 

https://www.dividendinvestor.com/dividend-news/20181120/dividend-announcement-pd-rx-pharmaceuticals-inc-otcbb-pdrx-on-11-20-2018-declared-a-dividend-of-$2.2000-per-share/

 

 

Shouldn't it be selling off given it's ex dividend date on a huge payout?

 

It is not ex dividend.  With large dividends the ex date is the day following the pay date.  In this case the pay date is 12/12 and the ex date is 12/13.

Link to comment
Share on other sites

Tim, I could be totally wrong here so bear with me.  If it is payable to shareholders on record November 30, isn't it now effectively ex-dividend?  Doesn't that imply I can sell my shares and still get the dividend?

No, because the ex date is 13 December. If you sell your shares you are the shareholder on record, but you will have sold the right to get the dividend with your shares so you won't get anything.

Link to comment
Share on other sites

  • 4 weeks later...

Decent year, boring as usual. I was secretly hoping that the huge dividend was paid out because of stellar results after the board announced it but the board has simply determined they are not going to acquire another business and/or invest heavily and are instead emptying the piggy bank for shareholders. Which is a very good thing, don't get me wrong.

 

Gross profit was actually very decent this year but an 800k increase in SG&A unfortunately means that net income was more or less the same as last year.

Link to comment
Share on other sites

Decent year, boring as usual. I was secretly hoping that the huge dividend was paid out because of stellar results after the board announced it but the board has simply determined they are not going to acquire another business and/or invest heavily and are instead emptying the piggy bank for shareholders. Which is a very good thing, don't get me wrong.

 

Gross profit was actually very decent this year but an 800k increase in SG&A unfortunately means that net income was more or less the same as last year.

 

Yeah, solid but unspectacular. Multiple has expanded as cash has been dividend-ed out, but @ ~6X EV/OP is still very reasonable.

 

Re the recent dividend: One possibility is that their results and/or outlook since FY 2018 ended have trended up strongly. Probably though, management has simply decided to stop hoarding cash.

 

 

 

Link to comment
Share on other sites

Results were a little disappointing it is true.  However, the dividend was a game changer.  This is a tiny micro-cap, that doesn't file with edgar.  There is a lot of trust involved here and seeing concrete actions, like paying 33% in dividends adds to that.  I only have a small stake but I will add if it drops a bit.  Revenue and earnings have been stalled for a few years, 12x earnings, no diversification, right now it feels fairly priced or maybe a touch cheap.  I like 10x earnings if growth is in question.

Link to comment
Share on other sites

Results were a little disappointing it is true.  However, the dividend was a game changer.  This is a tiny micro-cap, that doesn't file with edgar.  There is a lot of trust involved here and seeing concrete actions, like paying 33% in dividends adds to that.  I only have a small stake but I will add if it drops a bit.  Revenue and earnings have been stalled for a few years, 12x earnings, no diversification, right now it feels fairly priced or maybe a touch cheap.  I like 10x earnings if growth is in question.

 

Why are you using P/E ratio to value a company that, even after the recent dividend, has a large net cash position?

Link to comment
Share on other sites

I'd value them like a private buyer would, EV/OI.

 

I like that they're paying dividends, and I like the age of their senior execs.  I believe they're strongly correlated.  My prediction is this company is sold in the next 3-5 years.

 

The dividend has the smell of a "honey, let's spend some money now that the kids are out of the house" type feel.  The CEO is a family physician, still has a practice. Doctors seem to hang up the robe in their late 60s or early 70s.  A few go on forever, but I don't think that'll happen here.

 

I value this on a terminal value basis. Expect earnings will plug along, you get the cash back and the value of the company.  If you're curious as to what a company like this sells for call a few business brokers.  Depending on operations 8-10x EV/OI isn't unheard of, if someone can absorb them it might be a lot higher.  I don't think it goes for more than 1x sales, so say $10/share?  Things will continue as they have and then one day we'll be talking about the buyout with cash consideration.

 

Link to comment
Share on other sites

Thanks for the feedback.  1x sales would be amazing!

 

Reading through the annual report, I found this tidbit:

 

I am happy to report to you that we have done things well this year; sales are up, profit margins are difficult to hold but profits are up as well and we paid a dividend last year too.

I can report to you that sales for the FY 2018 were $24,967,418 down from last year’s sales of $25,987,783. 

We continue to be profitable with net earnings of $621,163 down from last year’s earnings of $626,966.

 

Why would they say sales are up and profits are up?  Their FY 2018 numbers clearly show sales and profit are down marginally.  Either this is a typo (very unlikely) or they are signalling that sales and profit for the year in progress are up..  2018 ended june 30, the special dividend was paid in December.  It is still very plausible that there was an improvement in the business which has lead to this substantial distribution..

 

Incidentally, I got a fill.  It is now a real position for me.

Link to comment
Share on other sites

Yeah, noticed that one as well in the annual report. I'm hoping that it's signaling something positive, and that it's not just a weird mistake.

 

Maybe this is what they mean? gross profit is up?

 

Net sales $ 24,967,418 $ 25,987,783

Cost of sales 16,432,161 18,149,421

Gross profit 8,535,257 7,838,362

Link to comment
Share on other sites

I looked at their 2017 report.  That line is exactly the same in 2017.  I am now thinking this was just a copy and paste error.  Microcaps..  Still in, but a little disappointed.

Yes, you are right. Looks like they were pretty lazy by copy and pasting the whole first paragraph...

Link to comment
Share on other sites

PDRX no longer sells opioid drugs.  They claim it caused insurance issues.  Does that play a role in the sales slowdown?

 

Please note:  PD-Rx will no longer offer opiate-based products as a result of the insurance carrier’s refusal to include all opiate-based products from its product liability policy.  You will be notified in the event of any future changes.

 

https://www.aaomsservices.org/asi_programs/view/pd_rx_pharmaceuticals

 

 

 

I saw this, that they are being sued for selling oxycodone, so I assume this switch was relatively recent.

 

A Kanawha County lawsuit is alleging HOPE Clinic, four medical professionals and two pharmacies are responsible for one man’s addiction and overdose death.

 

The case, filed June 29 by Inez Lewis, argues Timothy Jason Lewis, of Floyd County, Ky., was prescribed “highly addictive and potentially lethal drugs,” including oxycodone and methadone, with no medical purpose.

..

Inez filed another suit May 3 in Kanawha County Circuit Court on behalf of Timothy. Nine pharmaceutical companies, along with John Doe Doctors 1-25 and John Doe Health Care Facilities 1-25, were named as defendants.

 

The suit alleges the manufacturer defendants failed to warn about the risk of abuse, addiction and overdose death from the use of oxycodone and methadone.

 

The pharmaceutical defendants are: West-Ward Pharmaceuticals Corp. of Eatontown, N.J.; Roxane Laboratories Inc. of Columbus, Ohio; KVK-Tech Inc. of Newtown, Pa.; PD-RX Pharmaceuticals of Oklahoma City, Okla.;

 

https://www.bdtonline.com/news/lawsuit-claims-hope-clinics-are-responsible-for-overdose-addiction/article_c66f50de-8184-11e8-8f98-7380d7f5b2bd.html

 

That article is from July 2018. 

 

I am not really worried about this lawsuit, I assume this is just part of business in the US.  It's just one piece of the puzzle and may explain stalled sales.

Link to comment
Share on other sites

I'd value them like a private buyer would, EV/OI.

 

I like that they're paying dividends, and I like the age of their senior execs.  I believe they're strongly correlated.  My prediction is this company is sold in the next 3-5 years.

 

The dividend has the smell of a "honey, let's spend some money now that the kids are out of the house" type feel.  The CEO is a family physician, still has a practice. Doctors seem to hang up the robe in their late 60s or early 70s.  A few go on forever, but I don't think that'll happen here.

 

I value this on a terminal value basis. Expect earnings will plug along, you get the cash back and the value of the company.  If you're curious as to what a company like this sells for call a few business brokers.  Depending on operations 8-10x EV/OI isn't unheard of, if someone can absorb them it might be a lot higher.  I don't think it goes for more than 1x sales, so say $10/share?  Things will continue as they have and then one day we'll be talking about the buyout with cash consideration.

 

I found this little nugget on glass door, it relates to a sale of the company.  I have no idea if this is legit or some kind of plant but given it's 4 or 5 months old and hasn't surfaced yet, I assume it's the real deal.

 

I have been working at Pd-Rx Pharmaceuticals full-time

 

Pros

 

Management encourages a family atmosphere. Lots of long-tenured employees. Expectations are not too demanding. Co-workers and management are all pleasant, easy-going people.

 

Cons

 

The pay could be better. Rumor is the company is in the process of being sold. Hopefully the new ownership will maintain the company strong culture and ethics.

Link to comment
Share on other sites

I looked at their 2017 report.  That line is exactly the same in 2017.  I am now thinking this was just a copy and paste error.  Microcaps..  Still in, but a little disappointed.

Yes, you are right. Looks like they were pretty lazy by copy and pasting the whole first paragraph...

 

They changed their annual report. They had first updated a different annual report (see attached). I was lucky to snoop around on their website on New Years holiday.

Overall it  was well written, appreciated the candor with respect to Opiods.  I am slightly offended that they removed it and did a copy-paste on the previous year, but its likely profits in 2019 will suffer.

 

pdrx-pharmaceutical.pdf

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now



×
×
  • Create New...